2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Endometrial cancer

2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Tinker AV, Pothuri B, Gilbert L, et al

2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study

International Journal of Gynecologic Cancer 2022;32:A130.